Metropolitan Life Insurance Company (MetLife)’s Whitehawk Therapeutics WHWK Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio WHWK Stock Details WHWK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-812	Closed	-$5.55K	–	2456
2023 Q2	$5.55K	Buy	+812	New	+$6.31K	﹤0.01%	2448
2023 Q1	–	Sell	-934	Closed	-$12K	–	2482
2022 Q4	$12K	Buy	+934	New	+$12.2K	﹤0.01%	2225
2022 Q3	–	Sell	-906	Closed	-$11.2K	–	2366
2022 Q2	$11.2K	Buy	+906	New	+$13.5K	﹤0.01%	2296

Other funds holding WHWK

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s WHWK Position: Q3 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Whitehawk Therapeutics (WHWK) in Q3 2023, closing a stake of 812 shares — an estimated $5.55K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in WHWK in Q2 2022 and held it in 3 quarters. The position peaked at $12K in Q4 2022. 73 funds tracked by Wall St. Rank hold WHWK as of Q3 2023.

Metropolitan Life Insurance Company (MetLife) reported no remaining Whitehawk Therapeutics position as of Q3 2023 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 812 Whitehawk Therapeutics shares in Q3 2023, an estimated $5.55K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Whitehawk Therapeutics in Q2 2022 and held it in 3 quarters.
Metropolitan Life Insurance Company (MetLife)'s Whitehawk Therapeutics position peaked at $12K in Q4 2022.
73 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q3 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q3 2023, filed 14 Nov 2023.